Abstract: This invention relates to the therapeutic and prophylactic use of a combination including lactoperoxidase and at least one other component, with an isoelectric point of, or substantially above 6.8, and which are extracted from milk, to modulate the microbiome of an animal by selectively against at least one pathogenic microoganism.

Abstract: The present disclosure provides compositions and methods for improving disease resistance, increasing weight gain, and reducing the incidence and/or severity of clinical signs of infection. The composition generally comprises one or more microorganisms that is administered to an animal in need thereof. Preferred infections that can be combated with the compositions and methods of this disclosure are respiratory infections including PRRSV and PCV2.

Abstract: The present invention relates to infant formulas and follow-on formulas containing optimised amino acid profiles, in particular optimised amounts and/or ratios of phenylalanine. The formulas may contain intact proteins, hydrolysed proteins, protein fractions, free amino acids and/or a combination thereof selected based on their ability to provide the formula with an optimised amino acid profile. The present invention also relates to the administration of these formulas to infants in order to achieve balanced growth and/or development, for promoting, assisting or achieving balanced growth or development of the brain of an infant and/or the cognitive function of an infant, and may also assist in preventing or reducing the risk of obesity later in life.

Abstract: The present invention relates to a composition comprising at least one carboxylic acid selected from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid for use in treating a viral infection. Also disclosed is use of a composition comprising at least one carboxylic acid selected from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid in the manufacture of a medicament for treating a viral infection; and a method for treating a viral infection in a subject.

Abstract: The invention relates to a method for obtaining an N-acetylglucosamine containing neutral oligosaccharide from a fermentation broth, wherein said oligosaccharide is produced by culturing a genetically modified microorganism capable of producing said oligosaccharide from an internalized carbohydrate precursor, comprising the steps of: i) ultrafiltration (UF), preferably to separate biomass from the broth, ii) nanofiltration (NF), preferably to concentrate said oligosaccharide in the broth and/or reduce an inorganic salt content of the broth, and iii) treating the broth with an ion exchange resin, preferably to remove charged materials, and/or subjecting the broth to chromatography, preferably to remove hydrophobic impurities.

Abstract: Compositions including anti-viral compositions, therapeutic compositions, sunscreen compositions, skin treatment compositions, anti-aging compositions, and methods of making the same, are provided. Each composition includes milk fat globules (MFG) and may contain one or more agents encapsulated by the MFG. The unique nature of MFG provides an intact mammalian membrane containing proteins, glycoproteins, and carbohydrates found in mammary cells. By treating an infected patient with MFG, the MFG serve as a surrogate cell and interact with enveloped viruses, such as the COVID-19 coronavirus, the Herpes virus, and the Epstein Barr Virus, rendering them non-infectious. MFG derived from mammals can also be used to deliver pharmaceutical materials into an animal body such that the pharmaceutical materials bypass the venous blood and enter directly into the animal's lymphatic system. MFG allow the delivery of materials orally that could not heretofore have been delivered efficiently.

Abstract: A composition for eliciting a T-cell mediated immune response in a subject includes transfer factor from at least two different types of source animals. For example, the composition may include mammalian transfer factor and nonmammalian transfer factor. An example of the composition includes a combination of a colostrum-derived product, which includes the mammalian transfer factor, and an egg-derived product, which includes the nonmammalian transfer factor. Additionally, the egg-derived product may be substantially free of fat. Methods for forming the composition and eliciting T-cell mediated immune responses in subjects that have been treated with the composition are also disclosed.

Abstract: Compositions that include extracts from sources of immune modulators that include nanofraction immune modulator molecules (i.e., molecules having molecular weights of about 3,000 Da and less) are disclosed. These compositions may also include other immune modulators, such as transfer factor. Administration of compositions with extracts that include nanofraction immune modulator molecules modulates the cell-mediated immunity (e.g., down-regulates undesired T cell activity) of a subject to which such compositions are administered. When administered with transfer factor, the combination of nanofraction immune modulator molecules and transfer factor down-regulates undesired T cell activity while increasing, or up-regulating, T cell activity against pathogens and other undesirable entities, such as cancer cells and other aberrant or mutated cells. Assays and assay techniques for evaluating the immune modulation capabilities of various substances are also disclosed.

Abstract: Therapeutic compositions for addressing physiological stresses and aging include an immune modulator and one or more adaptogenic nutrients. Some non-limiting examples of immune modulators include as transfer factor, low molecular weight fraction immune modulators and/or other low molecular weight fractions of colostrum, egg or any other source of transfer factor or low molecular weight fraction immune modulators. Methods for administering immune modulators and adaptogenic nutrients to a subject to address the effects of physiological stresses and aging in the body of the subject, such as inflammatory responses, are also disclosed.

Abstract: The present invention relates to a composition of multivitamin vitamin B-C, particularly a composition of vitamin B-C for stimulating gastrointestinal (GI) system motility. The composition is suitable for preventing and/or treating conditions or diseases associated with insufficient GI motility.

Abstract: The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (HMOs).

Abstract: The application relates to synthetic compositions containing one or more human milk oligosaccharides for regulating satiety or reducing propensity to obesity.

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.

Abstract: Improving the antioxidant capacity in an animal by increasing the level of glutathione in the blood or tissue of the animal comprising providing a composition containing beta-casein to the animal for consumption, where the beta-casein comprises at least 75% by weight of one or more beta-caseins not capable of producing beta-casomorphin-7 on enzymatic digestion. Uses include as an oxidant, for treating or preventing the symptoms of cancer, inflammation, kwashiorkor (protein deficiency), seizure, autism, Down's syndrome, chronic fatigue syndrome, Alzheimer's disease, Parkinson's disease, sickle cell anaemia, liver disease, cystic fibrosis, HIV, AIDS, infection, heart attack, stroke, and diabetes, avoiding or reducing the effects of aging, promoting the recovery of tissue following physical exercise, and promoting fertility.

Abstract: Regulating the level of glucose in the blood of an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75% by weight beta-casein A2. Uses include managing the symptoms of hyperglycaemia and associated conditions including diabetes. The effect is both acute (post-exposure to the composition) and ongoing.

Abstract: The invention relates to a free glycine source for use in inducing tolerance against an allergen, or preventing the development of allergy in a human or other mammal. The invention further relates to a composition comprising protein, fat and carbohydrates with at least 7 en % protein and at least 60 mg free glycine source per gram protein, preferably at least 70 mg glycine per gram protein. The free glycine source is preferably the free amino acid glycine, a salt of the free amino acid glycine, or a combination thereof; the protein can be intact protein, hydrolysed protein, peptides, free amino acids, salts of amino acids, or combinations thereof.

Abstract: Compositions that include extracts from sources of immune modulators that include nanofraction immune modulator molecules (i.e., molecules having molecular weights of about 3,000 Da and less) are disclosed. These compositions may also include other immune modulators, such as transfer factor. Administration of compositions with extracts that include nanofraction immune modulator molecules modulates the cell-mediated immunity (e.g., down-regulates undesired T cell activity) of a subject to which such compositions are administered. When administered with transfer factor, the combination of nanofraction immune modulator molecules and transfer factor down-regulates undesired T cell activity while increasing, or up-regulating, T cell activity against pathogens and other undesirable entities, such as cancer cells and other aberrant or mutated cells. Assays and assay techniques for evaluating the immune modulation capabilities of various substances are also disclosed.

Abstract: Methods and systems to manufacture a soap bar comprising post-brew coffee particles are disclosed. A soap bar may comprise multiple post-brew coffee ground particle sizes to take advantage of the benefits associated with each size. For example, the soap bar may comprise espresso grinds (0.20 mm), regular grinds (1.0 mm), and/or coarse grinds (1.5 mm). A saponified fat base, e.g., a milk soap base, a plant oil base, and/or an animal fat base may be obtained and heated to a consistency. Collected post-brew coffee grounds may then be added. The coffee grounds may be anywhere from 1% to 65% of the total weight of the final product, depending on the desired soap quality. The final soap product may comprise coffee ground positive and coffee ground negative layers or portion, or the coffee grounds may be evenly dispersed throughout the product.

Abstract: A method includes obtaining training data for a plurality of patients of a patient population. The training data includes training blood glucose history data including treatment doses of insulin administered by the patients of the patient population and one or more outcome attributes associated with each treatment dose. The method also includes identifying, for each patient of the patient population, one or more optimum treatment doses of insulin from the treatment doses yielding favorable outcome attributes. The method also includes receiving patient-state information for the treated patient, determining a next recommended treatment dose of insulin for the treated patient based on one or more of the identified optimum treatment doses associated with the patients of the patient population having training patient-state information similar to the patient-state information for the treated patient, and transmitting the next recommended treatment dose to a portable device associated with the treated patient.

Abstract: The present invention relates to a novel composition with milk of immunized camelid, particularly, (Camelus dromedarius) as the main component (i.e. active ingredient) and a method for the treatment or prevention of gastrointestinal infections, particularly, infections caused by Escherichia coli (E. coli), Helicobacter Pylori (H. pylori), Campylobacter jejuni (C. jejuni), Salmonella enterica, Shigella dysenteriae, Clostridium perfringens, or Yersinia enterocolitica. Said composition is prepared in the form of pharmaceutical, nutraceutical, or health food preparations. The present invention also discloses a process of preparing said composition.

Abstract: Provided is a method of preparing a high-purity galactooligosaccharide composition by fermentation of a low-purity galactooligosaccharide mixture with a yeast strain, Kluyveromyces lactis ATCC 8585. The high-purity galactooligosaccharide composition includes at least 99% of galactooligosaccharides selected from the group consisting of galactotriose, galactotetrose, galactooligosaccharides with five or more sugar units, and combinations thereof and lower than 1% of monosaccharides and disaccharides. Also provided is a high-purity galactooligosaccharide composition and applications thereof in regulating blood glucose level and improving gut microbiota. For example, the high-purity galactooligosaccharide composition may be used to manufacture food products, beverages, health food products, nutritional supplements, and pharmaceutical compositions for patients or pets afflicted with diabetes mellitus or lactose intolerance.

Abstract: A therapeutic composition for wet and dry gangrene includes an herbal composition alone, or in combination with one or more animal-derived products. The herbal composition can include a mixture of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The mixture can include, for example, a mixture of extracts or whole herbs of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The one or more animal-derived products can include at least one of camel milk and camel saliva.

Abstract: The present invention provides very safe lactic acid bacteria and lactic acid bacteria preparations which are effective in prevention and therapy of allergies and/or in lowering of the blood neutral fat level. The present invention also provides pharmaceutical products and food or drink products which contain, as an active ingredient, a composition that contains cultured cells of the lactic acid bacterium Pediococcus acidilactici R037 or a treated product thereof.

Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.

Abstract: The present invention relates to a composition for removing keratinous skin material, the composition comprising a Lactobacillus strain or a culture thereof. Also, the present invention relates to a composition for removing keratinous skin material, the composition comprising green tea Lactobacillus as Lactobacillus. In contrast to when skin is improved through the supply of a moisture fraction by a commonly used skin-moisturizing component, the Lactobacillus according to the present invention removes keratinous skin material, thereby producing the advantageous effect that skin can be cared for and improved as the waste materials which accumulates on the skin is fundamentally removed. Therefore, the composition according to the present invention can effectively prevent or alleviate skin problems such as spots. Also, the invention regulates the skin and so improves skin tone by removing surplus keratinous material which is not needed by the skin.

Abstract: The invention relates to the production of compositions containing milk products for use as a nutritional supplement. More specifically, it relates to compositions containing whey growth factor extract, as well as their use in methods for reducing muscle inflammation in individuals undertaking resistance exercise training. According to one aspect of the invention, there is provided the use of a composition comprising whey growth factor extract, isolated from a milk product by cation exchange chromatography, to reduce exercise-induced muscle inflammation.

Abstract: Methods for improving the health of a female human or non-human animal are disclosed. The methods include the step of administering to the animal compositions including an effective amount of glycomacropeptide (GMP) for effectuating the methods. Specifically, the methods can be used to increase the rate of fat metabolism or fat oxidation, decrease percentage of body fat, increase the rate of bone mineralization, increase bone mineral content, increase bone mineral density, and/or increase bone strength in the animal. GMP-containing compositions can be used according to the disclosed methods to treat obesity and related metabolic conditions, or to treat or prevent osteoporosis, osteopenia, and other conditions related to loss of bone mineral content or bone strength.

Abstract: The subject invention provides compositions, and uses thereof, that improve gastrointestinal function. The compositions and methods of the subject invention are particularly advantageous for use with neonates because they can be used to stimulate development of the immature intestine in order to provide an enhanced ability to absorb nutrients and attain a stronger barrier function.

Abstract: The present invention relates generally to the field of neuronal health and neuronal protection. One embodiment of the present invention relates to a composition that can be used for the protection of the enteric nervous system from neurodegeneration. Disorders linked to an impaired enteric nervous system can be treated or prevented by the administration of lactoferrin containing compositions according to the present invention.

Abstract: Therapeutic compositions for addressing physiological stresses and aging include an immune modulator and one or more adaptogenic nutrients. Some non-limiting examples of immune modulators include as transfer factor, low molecular weight fraction immune modulators and/or other low molecular weight fractions of colostrum, egg or any other source of transfer factor or low molecular weight fraction immune modulators. Methods for administering immune modulators and adaptogenic nutrients to a subject to address the effects of physiological stresses and aging in the body of the subject, such as inflammatory responses, are also disclosed.

Abstract: An exfoliating body scrub composition is made from natural ingredients. The body scrub composition comprises ground coffee; ground whole oats; dry milk; from about 0.5% by weight to about 5% by weight of soy flour, based on the total weight of the coffee; oats; dry milk; and soy flour. The body scrub composition further comprises an optional carrier, such as an aqueous carrier, a moisturizing nonaqueous carrier, or a solid carrier. The body scrub composition may be made by combining solid ingredients comprising ground coffee, ground whole oats, dry milk, and from about 0.5% by weight to about 5% by weight of soy flour; and mixing the solid ingredients to produce a uniform powdered mixture. The uniform powdered mixture is optionally mixed with a carrier.

Abstract: The present invention concerns an improved balance of the essential branched chain amino acids leucine, isoleucine and valine in infant formula.

Abstract: This medicine is used treat Cancer, Pain and Bipolar. It can be taken as food or as a potent medicine in therapeutic effective amounts and potencies. It treats Cancer, depression, psychosis, manic symptoms, fear, Attention deficit symptoms, illness symptoms, pain, right lip retardation and removes bumps on the necks within a week or two. It is interchangeable in the ingredients. It can be combined with Pharmaceutical drugs and ingredients. It decreases the need for narcotics, cancer drugs or mental health drugs. It is extremely strong or potent and can be made weak or make your little ADD or Bipolar kid normal. It just has a continual ability. It is very potent.

Abstract: A nutritional product composition for increasing human growth hormone and nitric oxide production, to increase lean muscle mass, decrease body fat, and improve cardiovascular function and immune function. The nutritional product composition includes a synergistic blend of nutrients and a silica gel that increases the rate of metabolism of cells to increase the rate of absorption of the nutrients and elevate the production of the human growth hormone and elevate nitric oxide production. The synergistic blend of nutrients includes colostrum, L-arginine, potassium citrate and goji berry extract. The silica gel increases an absorption rate of the synergistic blend.

Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.

Abstract: A composition for diet supplementation to improve gut microflora is disclosed. The composition includes a prebiotic source and source of nucleotides, such as an extract of yeast. Also disclosed are methods of diet supplementation that include administering compositions of the invention to an individual.

Abstract: The use of a fermented milk product comprising non-hydrolysed whey proteins which is substantially free of casein proteins for the purpose of improving skin firmness, by structuring collagen without promoting collagen synthesis, when topically applied to skin is provided.

Abstract: This disclosure features human milk permeates and compositions containing the same obtained from fractionated whole human milk. The oligosaccharide rich permeate and permeate compositions of the present invention are useful as nutritional supplements for pre-term and full term infants, for establishing or maintaining gut flora and for treating the symptoms of inflammatory bowel disease.

Abstract: This invention relates to a formulation for the treatment of diabetes including 56 mg to 224 mg cow urine powder and 44 mg to 176 mg skim milk powder per kg body weight of the patient.

Abstract: The present invention provides a method of using Polygonum multiflorum or extracts thereof to enhance stem cell mobilization in a subject, including hematopoietic stem cells (HSCs) and bone marrow stem cells (BM-SCs). In one embodiment, a blended composition of plant parts, fruits, mushrooms, microorganisms, maternal fluids, and extracts thereof are used to promote mobilization of stem cells, resulting in migration of the stem cells to specific sties of maintenance and repair within tissues and/or organs. Increased circulation of HSCs and/or BMSCs and migration towards sites of maintenance promotes the natural regeneration mechanisms in the body.

Abstract: The present invention relates to fungicidal compositions and particularly fungicidal compositions comprising anhydrous milk fat (AMF), soybean oil and/or coconut fat. The invention also relates to a fungicidal method employing a composition of the invention. The compositions and methods of the invention have applications in the management (prevention and control) of fungal growth in commercial and small scale crop production.

Abstract: Biodegradable pharmaceutical compositions comprising 1,3-propanediol and its esters are provided. The 1,3-propanediol and its esters in the pharmaceutical composition are biologically derived, and as such, the pharmaceutical compositions exhibit a low anthropogenic CO2 emission profile.

Abstract: The present invention relates to topical vaginal compositions in gel form containing immune mediators, growth factors, chemotactic factors and antibacterial/antiviral factors extracted from bovine colostrum, and optionally other ingredients with complementary activity.

Abstract: Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising Boswellia gum, gel, resin or extract, Tea Tree oil (Melaleuca oil), an Aloe gel, resin, latex or extract and Lavender oil. The composition may be incorporated into a medical device such as a wound dressing or bandage, or formulated into a topical preparation such as an ointment, lotion or cream.

Abstract: A dietary product for preventing cardiometabolic risk in humans, in particular for reducing visceral fat and deep subcutaneous fat, includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or concentrate of whey, and calcium caseinate.

Abstract: The invention relates to whey protein micelles for use in the treatment and/or prevention of a disorder linked to an increase in insulin secretion and/or plasma IGF-1 concentration in an infant at risk of developing obesity or diabetes. The invention also relates to a nutritional composition for infants comprising whey protein micelles. Further, the invention relates to a non-therapeutic use of a nutritional composition for infants, comprising whey protein micelles.

Abstract: An enhancement composition includes a combination of natural ingredients that form a synergy to enhance the health, appearance, smell, and psyche of a surface, such as skin. Unnatural or processed ingredients are not included that can cause irritation and more detrimental effects to the skin. The enhancement composition has no preservatives because the particular combination of elements in the cream disclosed herein preserves the cream and permits a long shelf life. The enhancement composition is fabricated by combining, mixing, and sometimes heating predetermined amounts of Frankincense, Myrrh, black seed, and aloe. Additional ingredients can include, Shea butter, camel hump butter, coconut oil, olive oil, ginseng, natural resins, fatty acids, and various oils. The ingredients are combined by mixing, heating, cooling, distilling, or applying radiation. The composition promotes of spiritual health, particularly when implemented to include Frankincense and Myrrh.

Abstract: The disclosure features methods of making compositions that include a human lipid. The methods can include: obtaining whole human milk; separating the milk into a cream portion and a skim portion; processing the cream portion; and pasteurizing the processed cream portion.

Abstract: In one aspect, the disclosure provides formulations that stabilize proteins, wherein the formulations comprise a buffer. In some embodiments, the buffer comprises potassium mono-hydrogen-phosphate and potassium di-hydrogen-phosphate, or the buffer comprises sodium mono-hydrogen-phosphate and sodium di-hydrogen-phosphate. In some embodiments, the protein is a therapeutic protein. In some embodiments, the therapeutic protein is antithrombin.

Abstract: The invention provides topical compositions including vitamin A, colostrum (or extracts of colostrum with a high IGF content) with or without avian eggshell membrane, that stimulate the epidermis and dermis layers of the skin to treat skin aging.